O

Obio Technology Shanghai Corp Ltd
SSE:688238

Watchlist Manager
Obio Technology Shanghai Corp Ltd
SSE:688238
Watchlist
Price: 5.29 CNY -3.11% Market Closed
Market Cap: 3.4B CNY
Have any thoughts about
Obio Technology Shanghai Corp Ltd?
Write Note

Obio Technology Shanghai Corp Ltd
Accounts Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Obio Technology Shanghai Corp Ltd
Accounts Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
O
Obio Technology Shanghai Corp Ltd
SSE:688238
Accounts Receivables
ÂĄ89m
CAGR 3-Years
53%
CAGR 5-Years
62%
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Accounts Receivables
ÂĄ8.8B
CAGR 3-Years
19%
CAGR 5-Years
22%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Accounts Receivables
ÂĄ2.6B
CAGR 3-Years
25%
CAGR 5-Years
25%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Accounts Receivables
ÂĄ6.1B
CAGR 3-Years
28%
CAGR 5-Years
47%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Accounts Receivables
ÂĄ4.1B
CAGR 3-Years
32%
CAGR 5-Years
31%
CAGR 10-Years
33%
W
WuXi XDC Cayman Inc
HKEX:2268
Accounts Receivables
ÂĄ853.3m
CAGR 3-Years
225%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Obio Technology Shanghai Corp Ltd
Glance View

Market Cap
3.4B CNY
Industry
Life Sciences Tools & Services

Obio Technology Shanghai Corp. Ltd. engages in biomedical basic research, gene therapy drug incubation, and clinical grade gene therapy virus vector CDMO service provision. The company is headquartered in Shanghai, Shanghai and currently employs 631 full-time employees. The company went IPO on 2022-03-22. The firm is mainly engaged in providing contract research organization (CRO) services such as gene therapy vector development and gene function research for the basic research of gene therapy, as well as contract research and development production organization (CDMO) services such as pharmaceutical research and clinical sample production for the research and development of gene drugs. The firm mainly conducts business in the European and American markets and the domestic market.

Intrinsic Value
4.56 CNY
Overvaluation 14%
Intrinsic Value
Price
O

See Also

What is Obio Technology Shanghai Corp Ltd's Accounts Receivables?
Accounts Receivables
89m CNY

Based on the financial report for Dec 31, 2023, Obio Technology Shanghai Corp Ltd's Accounts Receivables amounts to 89m CNY.

What is Obio Technology Shanghai Corp Ltd's Accounts Receivables growth rate?
Accounts Receivables CAGR 5Y
62%

Over the last year, the Accounts Receivables growth was -7%. The average annual Accounts Receivables growth rates for Obio Technology Shanghai Corp Ltd have been 53% over the past three years , 62% over the past five years .

Back to Top